Skip to main content
Cassiopea files NDA for acne cream candidate

Cassiopea has filed a New Drug Application seeking the FDA's approval for its topical androgen receptor inhibitor cream clascoterone as a first-in-class acne treatment. The filing is supported by data from two of the company's late-stage trials testing the clascoterone cream or a vehicle cream over a 12-week period.

Full Story: